What Is Cerebrolysin? Benefits, Research & Safety
A multi-peptide neuroprotective preparation derived from porcine brain tissue, approved in some countries for stroke recovery and neurodegenerative conditions.
Quick Facts
Overview
Discovery & History
Mechanism of Action
[Molecular Structure Diagram Placeholder]
Researched Benefits
Based on preclinical and clinical research findings:
- 1Neuroprotection against excitotoxicity, oxidative stress, and apoptosis
- 2Enhancement of neuroplasticity and synaptic function
- 3Support for functional recovery after ischaemic stroke
- 4Potential cognitive improvement in Alzheimer's disease
- 5Promotion of neurogenesis from neural stem cells
- 6Improved outcomes in traumatic brain injury models
Theoretical Dosing & Protocols
| Theoretical Dosage | Clinical protocols use 10-30 mL IV daily for acute neurological conditions; 5-10 mL for chronic conditions |
| Frequency | Daily IV infusion for 10-21 day treatment cycles |
| Duration | Typical cycles of 10-21 days, repeated as clinically indicated |
| Notes | Administered by intravenous infusion in clinical settings. Not suitable for self-administration. Dosing determined by treating physician based on indication and severity. |
Administration Routes
Routes studied in research settings (educational only):
- Intravenous infusion
- Intramuscular injection (lower doses)
| Half-Life | Stability |
|---|---|
| Complex pharmacokinetics due to multi-peptide composition; clinical effects observed during and after treatment cycles | Supplied as a ready-to-use aqueous solution. Store at room temperature protected from light. |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Dizziness
- Headache
- Injection site reactions
- Agitation (rare)
- Mild gastrointestinal symptoms
Rare Risks & Concerns
- Allergic reactions
- Seizures in predisposed individuals (rare)
Contraindications
- Epilepsy
- Severe renal impairment
- Known hypersensitivity to porcine-derived products
- Pregnancy and breastfeeding
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not approved by the MHRA. Not available through standard UK prescribing.
🇪🇺 European Union
Approved in several EU member states (Austria, Germany, and others) for neurological indications.
Clinical Studies Summary
CASTA Trial — Cerebrolysin in Acute Ischaemic Stroke
A large randomised controlled trial of 1,070 acute ischaemic stroke patients comparing Cerebrolysin 30 mL/day to placebo for 10 days. While the primary endpoint showed trends toward improvement, predefined responder analysis showed significantly better outcomes in the Cerebrolysin group.
Cerebrolysin in Alzheimer's Disease
Multiple randomised controlled trials have evaluated Cerebrolysin in mild-to-moderate Alzheimer's disease. A Cochrane review found evidence of benefit on global clinical impression measures, though cognitive benefits were inconsistent across studies.
Cerebrolysin in Traumatic Brain Injury
Clinical studies suggest Cerebrolysin may improve functional outcomes after traumatic brain injury. The CAPTAIN trial demonstrated improved cognitive recovery in TBI patients receiving Cerebrolysin compared to placebo.
Looking for Cerebrolysin?
Source research-grade Cerebrolysin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Related Research Guides
Related Peptides
Selank
A synthetic peptide based on tuftsin, developed in Russia for anxiolytic and nootropic properties, approved there for anxiety and neurasthenia.
Learn moreSemax
A synthetic peptide based on ACTH, developed in Russia as a nootropic and neuroprotectant, approved there for cognitive disorders and stroke.
Learn moreDSIP
A neuropeptide originally isolated for its sleep-inducing properties, now researched for stress protection, pain modulation, and metabolic effects.
Learn moreBDNF
A critical growth factor for brain health, neuroplasticity, and neuronal survival, with implications for depression, memory, and neurodegenerative diseases.
Learn more